Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 541 participants.

Also called NCT06027307

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 541 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06027307
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06027307. Randomized; quadruple masking; primary purpose treatment. Start 2023-10-25 (actual); primary completion 2027-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
Acronym
EVENT
Condition
Tricuspid Regurgitation
Intervention (Drug)
Enavogliflozin
Intervention (Drug)
Placebo
Lead sponsor
Asan Medical Center (class: other)
Collaborator
Daewoong Pharmaceutical Co. LTD. (class: industry)

Record details

Record id
cardio:ct-nct06027307
Content hash
3d35487008503a41f11e6f550e76ac68a78daf577f8e30f943febecd6f9588d1